Amalya Sargsyan: Opening a new chapter in clinical trials for LMICs
Amalya Sargsyan shared a post on X:
“Opening a new chapter in clinical trials for LMICs!
Now recruiting for 1st-line Bal+Bot in stage IV NSCLC.
Just 1 week after our 1st trial launch, 1st patient already dosed. Super excited for results following promising CRC data.
Our Immune Oncology Research Institute spotlighted in ASCO policy statement on global equity in clinical trials!
With Armenia’s 1st oncology trials, we’re making our way to this global fight against cancer ‘Who if not us, will take these first steps?’ ”
Source: Amalya Sargsyan/X
Dr. Amalya Sargsyan is a Medical Oncologist at Yeolyan Center, a Research Physician at the Immune Oncology Research Institute, and Senior Editor at Oncodaily. She holds an MD from Yerevan State Medical University and an MSc in Precision Medicine from the University of Cyprus.
Dr. Sargsyan completed her clinical training at the Bank of Cyprus Oncology Center and has been honored with an ASCO IDEA award. Her research focuses on the potential of novel immune checkpoint inhibitors (ICI) in low- and middle-income countries (LMICs), aiming to bridge disparities and enhance access to innovative cancer care.
